IQVIA Holdings (IQV)
NYSE:IQV
Want to see IQV full AI Analyst Report?
IQV Stock Chart & Stats
$176.46
-$0.07(-0.03%)
At close: 4:00 PM EST
$176.46
-$0.07(-0.03%)
Day’s Range― - ―
52-Week Range$143.00 - $247.05
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.80M
Market Cap
$30.15B
Enterprise Value$30.54B
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$2.08B
Price to Earnings (P/E)22.0
Beta0.93
Next Earnings
Jul 28, 2026EPS Estimate
3.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.14
Shares Outstanding166,900,000
10 Day Avg. Volume1,892,692
30 Day Avg. Volume1,801,944
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit7.03
Enterprise Value/Ebitda8.69
Forecast
1Y Price Target
$213.90Price Target Upside21.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)12.8
Revenue Forecast (FY)$17.28B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent operating cash flow and strong free cash flow conversion (TTM nearly matches net income) provide durable internal funding for R&D, data investments and buybacks. Reliable cash generation underpins strategic flexibility and supports multi-year technology and service investments.
Large Bookings And BacklogA sizable backlog and strong R&D bookings give multi-quarter revenue visibility and steady project pipelines. The $8.9B slated to convert within 12 months supports near-term revenue, while a deep backlog underpins recurring services and capacity planning for sustained growth.
AI And Analytics AdoptionBroad AI adoption across top pharma clients enhances IQVIA's differentiated data+analytics moat, driving stickier subscriptions and cross-sell. Embedding AI into trial design, site ID and commercialization creates structural demand and higher-value service opportunities over the medium term.
Bears Say
Elevated LeverageHigh net leverage reduces financial flexibility and increases interest-rate sensitivity, constraining capital allocation during downturns. Sustained debt levels limit the firm's ability to fund opportunistic M&A or absorbing shocks without curbing buybacks or growth investments.
Margin Pressure And VolatilityMix shifts and FX-driven margin swings reduce margin predictability and can depress gross margins over multiple quarters. When pass-through work falls, fee-revenue mix shifts, compressing headline margins and making operating profitability more sensitive to client project composition.
Backlog Conversion Timing RiskLong and variable funding-to-award cycles create timing risk for translating bookings into awarded contracts and revenue. This lag can delay expected growth realization and complicate forecasting, especially when sponsor decision speeds remain below pre-disruption norms.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest stock price was $143.00 and its highest was $247.04 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $30.15B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s upcoming earnings report date is Jul 28, 2026 which is in 54 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on May 05, 2026. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.816 by $0.084.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 3.04.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 166,900,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of $2.9 in its last earnings report, beating expectations of $2.816. Following the earnings report the stock price went up 9.618%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$213.90 (21.22% Upside)
$213.90 (21.22% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.86%
12-Months-Change
Fundamentals
Return on Equity
22.46%
Trailing 12-Months
Asset Growth
8.61%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad strength: record revenue, EPS beat, double-digit bookings growth in R&D Solutions, accelerating organic growth in both Commercial and R&D segments, strong free cash flow and share repurchases, meaningful customer wins and rapid AI adoption. Near-term caveats included unusually low pass-throughs that depressed a headline book-to-bill metric, a ~60 bps EBITDA margin contraction driven by FX and mix, and elevated net leverage (3.62x). Management reaffirmed revenue and EBITDA guidance and raised EPS guidance. On balance, the positives materially outweigh the negatives.View all IQV earnings summariesIQV Revenue Breakdown
40.63% Technology & Analytics Solutions
54.54% Research & Development Solutions
4.83% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$213.90
▲(21.22% Upside)
Technical Analysis
Ownership Overview
0.98% Insiders
27.79% Mutual Funds
25.77% Other Institutional Investors
18.42% Public Companies and
Individual Investors